Clinical Trial Update: Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update on the safety, tolerability, and immunogenicity of the 24-valent pneumococcal conjugate vaccine VAX-24 in adults; study completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease
• Pneumococcal Infections

Drugs mentioned

• VAX-24 (24-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Vaxcyte, Inc. | Conditions: Pneumococcal Vaccines | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-04-18